BioPharmSignal logoBioPharmSignal

Biotech News

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics (ELVN)Enliven TherapeuticsFinancing

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public

Related news

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

View all latest news

Enliven Therapeutics

Precision Oncology Enliven Therapeutics develops small-molecule precision medicines intended to improve both survival and quality of life for people with cancer. ELVN-001 ELVN-001 is a selective BCR::ABL1 tyrosine-kinase inhibitor for chronic myeloid leukemia. It is designed to retain antileukemic activity while reducing off-target...

Recent company news

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

ELVNEnliven Therapeutics2026-06-11 20:05 EST

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

ELVNEnliven Therapeutics2026-06-11 12:00 EST

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

Stock data

Close
60.27 USD
Market cap
2.16B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States